Search Results - Therapeutics

7 Results

Sort By: Published Date Updated Date Title ID Descending Ascending

Novel Compounds for the Treatment of Diarrheal Diseases Executive SummaryUniversity of Virginia researchers have created novel derivative compounds of FDA-approved drug Nitazoxanide (NTZ) that show reduced toxicity, improved bioavailability and greater efficacy against a range of organisms that cause diarrheal diseases. BackgroundDiarrheal diseases are especially common in children, immuno-compromised individuals,... Published: 3/8/2012   |   Inventor(s): Timothy Macdonald, Richard Guerrant, Paul Hoffman, Thomas Ballard Keywords(s): Therapeutics Category(s): Therapeutics

Novel Compounds for Prevention and Treatment of Bacterial Infections and Biofilms Executive SummaryUniversity of Virginia researchers have created novel derivative compounds of FDA-approved drug Nitazoxanide (NTZ) that show reduced toxicity, improved bioavailability and greater efficacy against bacterial infections and biofilms.BackgroundOpportunistic hospital-acquired pathogens, including S. epidermidis and S. aureus, are the leading... Published: 3/8/2012   |   Inventor(s): Timothy Macdonald, Richard Guerrant, Paul Hoffman, Thomas Ballard Keywords(s): Therapeutics Category(s): Therapeutics

Use of Monoclonal Antibodies to Target Cancer Cells The use of monoclonal antibodies in cancer diagnosis and treatment, while promising, is also problematic. Current cancer therapies that rely on this technology require the identification of specific epitopes that are expressed at high levels for a given form of cancer but are expressed at low levels on normal tissues and the development of monoclonal... Published: 3/8/2012   |   Inventor(s): Ronald Taylor, Alessandra Nardin, William Sutherland, Mitchell Sokoloff, Leland Chung, Michael Solga Keywords(s): Therapeutics Category(s): Therapeutics

Novel Targets in Treating Erectile Dysfunction Courtesy Lysiak, Palmer, Kavoussi Figure 1. Heterozygote and knockout mice are unable to maintain erections. When the cavernous nerve is stimulated, wild type mice (blue) are able to maintain high intracavernous pressures (ICPs) for approximately five minutes, whereas both heterozygote (green) and... Published: 3/8/2012   |   Inventor(s): Jeffrey Lysiak, Lisa Palmer, Parviz Kavoussi Keywords(s): Therapeutics Category(s): Therapeutics

Targeted Treatment for the Inv(16) Subtype of Acute Myeloid Leukemia Executive SummaryUniversity of Virginia researchers have discovered novel compounds that can be used for the targeted treatment of the inv(16) subtype of Acute Myeloid Leukemia (AML), improving upon existing nonspecific chemotherapies. These compounds have the promise to vastly improve patients’ therapy tolerance, survival rates and relapse rates.... Published: 3/8/2012   |   Inventor(s): John Bushweller, Jolanta Grembecka, Anuradha Illendula, Lauren Dixon Keywords(s): Therapeutics Category(s): Therapeutics

Thermally Responsive Composite Hydrogel Executive SummaryThe purpose of the invention is to produce a thermally sensitive hydrogel, which is a liquid at room temperature and solid at physiological temperature. The hydrogel can be injected at an injury site to deliver therapeutic agents. BackgroundThe products used currently in orthopedic surgery for delivery of protein are flimsy, collagen... Published: 3/8/2012   |   Inventor(s): Joshua Bush Keywords(s): Therapeutics Category(s): Therapeutics

Oral General Anesthetics and Metabolically Resistant Anticonvulsants Executive SummaryA researcher at the University of Virginia has discovered a group of novel compounds that have activity as anesthetics, anticonvulsants and neuroprotective agents. These compounds are unique in that they have been modified to prevent the formation of a common toxic metabolite.BackgroundThemisone has been widely utilized as an anticonvulsant... Published: 3/8/2012   |   Inventor(s): Milton Brown Keywords(s): Therapeutics Category(s): Therapeutics